23 Jul, 2026
According to Straits Research the global breast cancer liquid biopsy market was valued at $1.26 billion in 2025 and is anticipated to reach $2.73 billion by 2034, registering a CAGR of 8.4% during the forecast period 2026–2034.
The breast cancer liquid biopsy market is experiencing rapid growth, driven by supportive government initiatives, a focus on early detection, and regulatory backing. Programs like Kerala’s 2025 “Arogyam Anandam - Keep Cancer at Bay” campaign are expanding access to screenings and raising public awareness, promoting the adoption of minimally invasive diagnostics such as liquid biopsy. These tests analyze circulating tumor markers, such as ctDNA, enabling early detection before clinical symptoms appear, improving patient compliance, and supporting personalized treatment strategies. Regulatory support for test approvals encourages innovation and market entry, increasing availability and competition.
However, growth is restrained by a lack of standardization, inconsistent biomarker detection methods, interpretation challenges, and limited reimbursement frameworks. Opportunities lie in population-level screening, particularly for high-risk individuals, as liquid biopsy can complement mammography by detecting early-stage mutations or epigenetic changes. Research on cfDNA methylation and microRNA cargoes promises cost-effective, high-throughput assays, potentially transforming early diagnosis, improving survival outcomes, and providing a competitive advantage in preventive oncology.
sales@straitsresearch.com